

Application No. 10/069,018
Amendment dated October 1, 2003
Page 10

REMARKS/ARGUMENTS

Preliminarily, the Applicants would like to thank the Examiner for allowing claims 3-5, 11-14 and 17, presented substantially as new claims 28-30, 36-39 and 41. The Applicants submit that the remaining claims are allowable as well.

Upon entry of the above amendments claims 1-25 will be cancelled and claims 26-47 will be pending. No new matter has been introduced.

Claims 6-10, 15, 16 and 18-25 stand rejected under 35 U.S.C. §112, second paragraph, as being indefinite. The Applicants assert that the above amendments place the claims in full compliance with §112. Accordingly, the Applicants respectfully request reconsideration and withdrawal of this rejection.

Claims 1, 2, 6-7 and 10 stand rejected under 35 U.S.C. §102(b) as anticipated by Okubu (US 3,401,048, specifically column 5, line 6) or Overlinner (DE 23 33 378, specifically examples 23 and 24). In addition, claims 1, 2 and 6-8 stand rejected under 35 U.S.C. §102(b) as anticipated by Hauser (*Helv. Chim. Acta.*, 11, 198-209 (1928), specifically p. 203, and compounds 1, 7, 9 and 10). The Applicants traverse these rejections for at least the following reasons.

The claims as presently pending are free of the cited art. Specifically, none of the cited art disclose a compound, pharmaceutical formulation, medicinal preparation, or a method of reducing or inhibiting cancer cell growth, with a compound of Formula I wherein R^1 represents fluoro, iodo or trimethyltin; R^2 represents alkyl, a halo substituted or hydroxy substituted alkyl, hydroxyl, alkoxy or aralkoxy, and when n represents zero, R^3 or R^6 represents $-C(Y)-CH(R^4)NH_2$. Since the cited art does not anticipate the present invention, the Applicants respectfully request reconsideration and withdrawal of this rejection.

Therefore, all objections and rejections having been addressed, it is respectfully submitted that the present application is in a condition for allowance and a Notice to that effect is earnestly solicited.

Application No. 10/069,018
Amendment dated October 1, 2003
Page 11

Should any issues remain unresolved, the Examiner is encouraged to contact the undersigned attorney for Applicants at the telephone number indicated below in order to expeditiously resolve any remaining issues.

Respectfully submitted,

PILLSBURY WINTHROP LLP

By: 

Christopher M. Beck
Registration No. 52,603
Direct No. (703) 905-2013

Paul L. Sharer
Registration No. 36,004
Direct No. (703) 905-2180

PLS/CMB
1600 Tysons Boulevard
McLean, VA 22101
(703) 905-2000 Telephone
(703) 905-2500 Facsimile

Date: October 1, 2003